American Journal of Cardiovascular Drugs

, Volume 6, Issue 5, pp 343–348

The Effect of Moxonidine on Endothelial Dysfunction in Metabolic Syndrome

  • Ergun Topal
  • Ayse Sertkaya Cikim
  • Kerim Cikim
  • Ismail Temel
  • Ramazan Ozdemir
Original Research Article

DOI: 10.2165/00129784-200606050-00007

Cite this article as:
Topal, E., Cikim, A.S., Cikim, K. et al. Am J Cardiovasc Drugs (2006) 6: 343. doi:10.2165/00129784-200606050-00007

Abstract

Background

Endothelial dysfunction has been reported in patients with type 2 diabetes mellitus and even in healthy obese individuals with a normal metabolic profile. Sympathetic activity commonly is increased in obese hypertensive patients, and moxonidine is effective in lowering BP and improving insulin sensitivity.

Objective

To evaluate the effect of moxonidine on endothelial dysfunction in patients with metabolic syndrome.

Methods

Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone. Anthropometric (body mass index, waist and hip circumferences, and waist-to-hip ratio) and metabolic features (fasting plasma glucose and insulin, aminotransferases, γ-glutamyl transpeptidase, triglycerides, and cholesterol levels) and flow-mediated dilatation (FMD) were evaluated. Insulin resistance was calculated by using the homeostasis model assessment formula. Insulin sensitivity was calculated according to the quantitative insulin-sensitivity check index (QUICKI).

Results

SBP and DBP (both p < 0.001) and waist circumference (p = 0.02) were higher, and QUICKI (p = 0.043) and FMD (p = 0.01) were lower in the hypertensive group at baseline. After 3 months, nearly all the study parameters improved in both treatment groups. The decrease in BP, increase in FMD, and improvements in metabolic and anthropometric parameters were significantly greater in the moxonidine-treated group than in those treated with diet alone.

Conclusion

Moxonidine is proposed as a valuable option for treating mild-to-moderate hypertension in obese and insulin-resistant patients with metabolic syndrome as it appears to improve endothelial dysfunction in these patients.

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Ergun Topal
    • 1
  • Ayse Sertkaya Cikim
    • 2
  • Kerim Cikim
    • 3
  • Ismail Temel
    • 4
  • Ramazan Ozdemir
    • 1
  1. 1.Department of CardiologyInonu University Faculty of MedicineMalatyaTurkey
  2. 2.Department of Internal Medicine, Division of Endocrinology and MetabolismInonu University Faculty of MedicineMalatyaTurkey
  3. 3.Department of Internal MedicineInonu University Faculty of MedicineMalatyaTurkey
  4. 4.Department of BiochemistryInonu University Faculty of MedicineMalatyaTurkey